Multiple Sclerosis

LIST OF CLINICAL TRIALS BY THERAPEUTIC AREA

  • CARDIOLOGY

  • ENDOCRINOLOGY

  • MULTIPLE ESCLEROSIS

  • RARE DISEASES

MULTIPLE SCLEROSIS

Drug: Alemtuzumab

Manufacturer: Genzyme

Indication: Multiple sclerosis

  1. Study: A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon Beta-1a (Rabif®) in patients with relapsing-remitting multiple sclerosis who have been relapsed on therapy.
    • Role: Clinical operations: feasibility, site selection, site management in Latin America, global Steering Committee
    • Status: published

 

  1. Study: A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon Beta-1a (Rabif®) in patients with relapsing-remitting multiple sclerosis previously untreated.
    • Role: Clinical operations: feasibility, site selection, site management in Latin America, global Steering Committee
    • Status: published